A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)
Phase of Trial: Phase II
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Sapanisertib (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 11 Jul 2017 Planned number of patients changed from 31 to 35.
- 11 Jul 2017 Planned End Date changed from 1 Dec 2017 to 31 May 2020.
- 10 Jun 2017 Biomarkers information updated